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Abstract
Representative animal models for diabetes-associated vascular complications are extremely relevant in assessing potential
therapeutic drugs. While several rodent models for type 2 diabetes (T2D) are available, their relevance in recapitulating renal
and cardiovascular features of diabetes in man is not entirely clear. Here we evaluate at the molecular level the similarity
between Zucker diabetic fatty (ZDF) rats, as a model of T2D-associated vascular complications, and human disease by
urinary proteome analysis. Urine analysis of ZDF rats at early and late stages of disease compared to age- matched LEAN rats
identified 180 peptides as potentially associated with diabetes complications. Overlaps with human chronic kidney disease
(CKD) and cardiovascular disease (CVD) biomarkers were observed, corresponding to proteins marking kidney damage (eg
albumin, alpha-1 antitrypsin) or related to disease development (collagen). Concordance in regulation of these peptides in
rats versus humans was more pronounced in the CVD compared to the CKD panels. In addition, disease-associated
predicted protease activities in ZDF rats showed higher similarities to the predicted activities in human CVD. Based on
urinary peptidomic analysis, the ZDF rat model displays similarity to human CVD but might not be the most appropriate
model to display human CKD on a molecular level.
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Introduction
Type 2 diabetes (T2D) is characterized by progressive failure of
pancreatic insulin secretion to compensate for increased peripheral
insulin resistance resulting in chronic hyperglycemia [1]. The
prevalence of this common disorder has risen alarmingly in the
past decade, in part due to increased obesity and sedentary
lifestyle. Today, more than 346 million people worldwide are
affected, and T2D is becoming an increasingly serious medical and
- due to its costs - socio-economic issue [2].
Chronic hyperglycemia mostly affects the human vascular tree
and promotes the development of micro- and macrovascular
disease. About 30–40% of all patients develop microvascular
disease, including retinopathy, and diabetic nephropathy (DN).
Macrovascular disease in diabetic individuals affects the coronary,
carotid and peripheral arteries, increasing the risk of myocardial
infarction, stroke and diabetic foot disease [3]. The risk for
cardiovascular (CV) events is 2- to 4- fold increased in diabetic
patients as compared to patients without diabetes [4] and CV
diseases (CVD) are responsible for up to 80% of premature excess
morbidity and mortality in T2D. The development of these
vascular complications is a complex and heterogeneous process,
starting years before the onset of clinical symptoms. The ‘Cost of
Diabetes in Europe - Type II study’ (CODE-2 study) that included
data on 7000 people with T2D from eight European studies
showed that 72% of the T2D patients had at least one
complication and 24% had both, microvascular and macrovas-
cular, complications [5].
We previously identified urinary biomarkers of CKD [6] and
CVD [7] in different patient populations (diabetics and non-
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diabetics) using capillary electrophoresis coupled with mass
spectrometry (CE/MS). Importantly, these urinary proteomic
biomarkers have been validated and their association with CKD
and DN (in the case of the CKD panel) and CVD (in the case of
the CVD panel) was demonstrated in several large scale blinded
studies [6–9].
Pre-clinical animal models are essential tools to gain a deeper
understanding of the underlying pathophysiological changes
leading to the development of T2D as well as its complications.
Such models are mandatory for the development of therapeutic
intervention for diabetes associated complications. Ideally, the
animal models should display high similarity to the human disease
on a molecular level.
To assess molecular similarity, we performed urinary proteome
analysis in Zucker diabetic fatty (ZDF) rats on high fat diet, a
recognized model of obesity, T2D, arterial hypertension and
hyperlipidemia, that develop progressively diabetes-specific end-
organ-damages [10,11], and investigated the similarity between
the human disease and the animal model on the molecular,
urinary proteome level.
Materials and Methods
Animal Experiments
Male Zucker diabetic fatty (ZDF) rats (ZDF/Gmi-fa/fa; n = 20)
and age matched LEAN control rats (ZDF/Gmi-fa/+; n = 17)
were purchased from Charles River Laboratories Italia S.r.l.,
Calco, Italy, and housed in a constant temperature room with a
12-h dark/12-h light cycle. ZDF rats received high fat Purina 5008
diet (Charles River) to accelerate the development of the disease.
Animal care and treatments were all conducted in conformity with
the institutional guidelines that are in compliance with national
(DecretoLegislativo n.116, GazzettaUfficialesuppl 40, 18 febbraio
1992, Circolare n.8, GazzettaUfficiale 14 luglio 1994) and
international laws and policies (EEC Council Directive 86/609,
OJL358-1, December 1987; Guide for the Care and Use of
Laboratory Animals, US National Research Council, 1996).
Animal studies were submitted to and approved by the Institu-
tional Animal Care and Use Committee of Mario Negri Institute,
Milan, Italy.
A group of ZDF (n = 10) and LEAN(n = 10) rats was studied at 2
months of age, the remaining ZDF (n = 10) and LEAN(n = 7) rats
at 8 months of age. Blood glucose levels were assessed with an
Ascensia glucometer (Bayer Diagnostics, Milan, Italy), serum
cholesterol, triglycerides, and blood urea levels were measured by
a Reflotron test (Roche Diagnostics, Indianapolis, USA). For the
assessment of proteinuria, 24-hurine samples were collected using
metabolic cages (Tecniplast, Varese, Italy)and proteinuria deter-
mined by the Coomassie method using a Cobas Mira plus
autoanalyzer (Roche Diagnostic System, Basel, Switzerland).
Serum and urinary creatinine were measured by Cobas Mira
plus autoanalyzer (Roche Diagnostic System). Creatinine clear-
ance rate was calculated as urinary creatinine X urine volume/
serum creatinine and expressed as millilitres per minute. Systolic
blood pressure (SBP) was measured in conscious rats with an
occlusive tailcuffplethysmograph attached to a pneumatic pulse
transducer with the BP-2000 BP analysis system (Visitech Systems,
Apex, NC).
We obtained renal and cardiac tissue for morphologic and
immunohistochemical analyses from the animals at 2 and 8
months of age. Kidneys were fixed overnight in Duboscq-Brazil,
dehydrated in alcohol, and embedded in paraffin. Three-
micrometer sections (Ultrotome V, LKB, Bromma, Sweden) were
stained with hematoxylin and eosin and periodic acid-Schiff
reagent. At least 100 glomeruli, including superficial and
juxtaglomerullary cortical area, were examined for each animal.
The extent of glomerular damage was expressed as the percentage
of sclerotic glomeruli. Tubular damage in the tissue sections was
evaluated as number of casts per high power field (HPF).
Immunohistochemistry was performed on paraffin- embedded
sections. Detection of monocyte/macrophage ED-1 surface
antigen was performed by alkaline phosphatase- fast red technique
using mouse monoclonal antibodies (1:100, Chemicon, Temecula,
USA). Positive cells were counted on an average of 30 randomly
selected interstitial high- power fields (400x) for each animal. Type
III collagen was detected by the ABC immunoperoxidase method
using polyclonal rabbit anti-rat type III collagen antibody (1:100,
Chemicon). Visualization was performed by diaminobenzidine.
The signal intensity was graded using the following scoring system:
0, no; 1, weak; 2, moderate; and 3, strong expression in at least 20
randomly selected high power fields (400x).
For cardiac histology, sections of the left ventricle (LV) were cut
perpendicularly to its longitudinal axis and fixed in 4% neutral
buffered formalin, for paraffin embedded sections.
Sample Characteristic
Urine samples were collected from n = 10 ZDF and n = 10
LEANrats at 2 months of age and from n = 10 ZDF and n = 7
LEAN rats at 8 months of age. Collection was performed over a
period of 24 hours in metabolic cages. Results for sample
characteristic are expressed as mean 6SD. Data were analyzed
using ANOVA coupled with Bonferroni post hoc analysis.
Statistical significance level was defined as P,0.05.
Sample Preparation
Immediately before preparation rat urine aliquots were thawed
and 150 ml were mixed with 150 ml of 2 M urea, 10 mM NH4OH
containing 0.02% SDS. Subsequently, samples were ultrafiltered
using a Centristat 20 kDa cut-off centrifugal filter device (Satorius,
Go¨ttingen, Germany) to eliminate high molecular weight com-
pounds. The obtained filtrate was desalted using a NAP5 gel
filtration column (GE Healthcare Bio Sciences, Uppsala, Sweden)
to remove urea and electrolytes. The sample was lyophilized in a
Christ Speed-Vac RVC 2 18/Alpha 1 2 (Christ, Osterode am
Harz, Germany) and stored at 4uC until use. Finally, shortly before
CE/MS analysis, the samples were re-suspended in 10 mL HPLC-
grade H2O. Samples were injected into CE-MS with 2 psi for
99 sec, resulting in injection volumes of ,280 nL.
CE-MS Analysis
CE-MS analysis was performed as described [12] using a P/
ACE MDQ capillary electrophoresis system (Beckman Coulter,
Fullerton, USA) on-line coupled to a MicroTOF MS (Bruker). The
ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was
grounded, and the ion spray interface potential was set –4.5 kV.
Data acquisition and MS acquisition methods were automatically
controlled by the CE via contact-close-relays. Spectra were
accumulated every 3 s, over a range of m/z 350 to 3000.
Data Processing and Cluster Analysis
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisusoftware [13]. Migration time and ion signal
intensity (amplitude) were normalized using internal polypeptide
standards, as described elsewhere [12]. The resulting peak list
characterizes each polypeptide by its molecular mass [Da],
normalized migration time [min] and signal intensity. All detected
ZDF Rat as a Model for Human Disease
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polypeptides were deposited, matched, and annotated in a
Microsoft SQL database. During initial clustering, polypeptides
within different samples were considered identical, if the mass
deviation was lower than 650 ppm for masses ,4.000 Da, for
masses between 4.000 and 6.000 Da the 50 ppm entities gradually
increasing to 6150 ppm and 150 ppm for features .6 kDa.
Acceptable migration time deviation was,61 minutes for 19 min,
gradually increasing to,62.5 min at 50 min.
Statistical Analysis for Biomarker Definition
For the identification of potential biomarkers, the reported p-
values were calculated using the Wicoxon Rank-Sum test followed
by adjustment for multiple testing using the method described by
Benjamini and Hochberg [14] Only proteins/peptides that were
detected in a frequency of $70% in at least one of the diagnostic
groups were considered for statistical analysis.
Sequencing
The urine samples were analysed on a Dionex Ultimate 3000
RSLS nano flow system (Dionex, Camberly UK). The samples
(5 ml) were loaded onto a Dionex 100 mm62 cm 5 mm C18 nano
trap column at a flowrate of 5 ml/min by a Ultimate 3000 RS
autosampler (Dionex, Camberley UK) The composition of the
loading solution was 0.1% formic acid and acetonitrile (98:2).
Once loaded onto the trap column the sample was then washed off
into an Acclaim PepMap C18 nano column 75 mm615 cm, 2 mm
100 A˚ at a flow rate of 0.3 mm/min. The trap and nano flow
column were maintained at 35uC in a column oven in the
Ultimate 3000 RSLC.
The eluent from the column was directed to a Proxeonnano
spray ESI source (Thermo Fisher Hemel UK) operating in positive
ion mode then into an OrbitrapVelos FTMS. The ionisation
voltage was 2.5 kV and the capillary temperature was 200uC. The
mass spectrometer was operated in MS/MS mode scanning from
380 to 2000 amu. The fragmentation method was HCD at 35%
collision energy. The ions were selected for MS2 using a data
dependant method with a repeat count of 1 and repeat and
exclusion time of 15 s. Precursor ions with a charge state of 1 were
rejected. The resolution of ions in MS1 was 60,000 and 7,500 for
HCD MS2.
Data files from experiments performed on the HCD-enabled
LTQ were searched against the IPI rat non-redundant database
using the Open Mass Spectrometry Search Algorithm (OMSSA,
http://pubchem.ncbi.nlm.nih.gov/omssa) and SEQUEST (by
using Thermo Proteome Discoverer), without any enzyme
specificity. No fixed modification was selected, and oxidation of
methionine and proline were set as variable modifications. Mass
error window of 10 ppm and 0.05 Da were allowed for MS and
MS/MS, respectively. In the case of SEQUEST, the peptide data
were extracted using high peptide confidence and top one peptide
rank filters. The OMSSA results were further optimized by the use
of the FDA Optimizer [15] 1% FDR was used as a cut-off value
for reporting identified peptides. Accepted were peptides which
Figure 1. Study design. For biomarker definition urine samples of ZDF and LEAN control rats were used. The defined ZDF rat biomarkers at the late
stage of disease (8 months) were compared based on the orthology of amino acid sequences, to the human CKD and CVD biomarkers. The overlap in
sequenced urine peptide markers between early (2 months) and late stage disease ZDF rat markers is given in the Venn-diagram.
doi:10.1371/journal.pone.0051334.g001
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were found with both search algorithms (OMSSA and SE-
QUEST), only with a mass deviation below 680 ppm.
For further validation of obtained peptide identifications, the
strict correlation between peptide charge at the working pH of 2
and CE-migration time was utilized to minimize false-positive
identification rates [16]: Calculated CE-migration time of the
sequence candidate based on its peptide sequence (number of basic
amino acids) was compared to the experimental migration time.
CE-migration time deviations below 62 min corresponding to the
CE-MS measurement were accepted.
Protease Identification
A strict and a relaxed identification procedure was applied, to
expand the number of potential protease involved in peptide
generation. All peptide sequences were mapped to the full-length
protein sequence and all complete cleavage sites: for peptide N-
terminus, three amino acids from protein sequence before peptide
start and three amino acids from peptide sequence after peptide
start; for peptide C-terminus, three amino acids from peptide
sequence before peptide end and three amino acids from protein
sequence after peptide end. An in-house curated MEROPS/
CutDB database (http://cutdb.burnham.org/) was used to search
the six amino acids cleavage sites for matches to any of the
protease cleavage sites in the database. As a next step, a relaxed
search was conducted by mapping the cleavage sites to the
database allowing up to 2 amino acids mismatches.
Results and Discussion
To our knowledge, this study is the first to identify specific
urinary peptides associated with diabetes-related complications in
the ZDF rat model and to evaluate the similarity of this model to
human urinary peptide markers for micro- and macrovascular
complications. The study design is graphically depicted in
Figure 1.
Sample Characteristics
Characteristics for the sample cohort are given in Table 1.
The ZDF rats were heavier than LEAN rats at 2 months of
age. As in previous studies [10], the body weight of ZDF rats
stabilized and was lower than that of LEAN rats at 8 months of
age. Consistent with a diabetic phenotype, ZDF rats were
hyperglycaemic, and dyslipidaemic compared with LEAN rats
already at early (2 months of age) and more severely at late
stage (8 months of age). Renal function was significantly
impaired in ZDF rats at 8 months as indicated by increased
BUN levels and reduced creatinine clearance. Proteinuria was
already present at 2 months and progressively increased at 8
months in ZDF rats. No glomerular and tubulo-interstitial
changes were observed at 2 months. By contrast, at 8 months in
ZDF rats renal histology showed pathological changes, including
glomerular sclerosis with thickening of the Bowman’s capsule
and retraction of the tuft, tubular atrophy and dilation, and
hyaline casts (Table 1, Figure 2a). Interstitial inflammation
and accumulation of interstitial type III collagen were also
observed (Table 1). In contrast, LEAN rats did not develop
any histopathological changes. Blood pressure increased steadily
in ZDF rats, while LEAN control rats had stable blood pressure
during the experimental period (Figure 2b). ZDF rats showed
an enlarged cardiomyocyte surface area compared to LEAN
control animals at late stage of disease (Figure 2c). In addition,
cardiac microvascular density was reduced in ZDF rats
compared to LEAN control rats (Figure 2d) at both early
and late stages of disease.
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CE/MS Analysis of Low Molecular Urinary Proteome
Pattern in ZDF and LEAN Rats
From all urine samples high quality CE/MS data could be
obtained. The compiled contour plots of early (2 months of age)
and late (8 months of age) stage ZDF rats as well as LEAN control
rats are displayed in Figure 3.
Definition of Urinary Rat Late Stage Disease Markers and
Comparison with Human Urinary Peptide Markers for
Chronic Kidney (CKD) and Cardiovascular Disease (CVD)
For biomarker identification, we used urine samples from
LEAN control (n = 7) and ZDF rats (n = 10) at month 8. We
hypothesized that these markers should be associated with
diabetes, diabetes-associated complications, or both. The compar-
ison of the abundance of individual urinary peptides between cases
and controls resulted in the identification of 531 peptides with
significantly altered urinary excretion levels when adjusting for
multiple testing (P-value ,0.05). Sequencing information was
obtained for 180 of the 531 marker candidates (Figure 1). The
amino acid sequences, protein names, start and stop positions are
all listed in Table S1. Two or more peptides originating from
aminopeptidase N, apolipoprotein IV, collagen, contrapsin-like
protease inhibitor, hemoglobin, osteopontin, proline-rich protein,
seminal vesicle secretory protein, SMR1 and uromodulin were
identified.
To assess similarity to human CKD and CVD, we compared
the 180 rodent biomarkers of late stage disease with human
urinary biomarkers of CKD (panel includes 273 sequenced
biomarkers) [6] and CVD (panel includes 99 sequenced biomark-
ers) [7]. To focus on the most relevant disease-associated changes,
the 50 most significant peptides (lowest P-values) in the CKD
(Table S2) and CVD (Table S3) human panels were compared
to the rat biomarkers. However, similar results (in terms of
similarities in precursor proteins and trends of expression) were
achieved when comparing all the peptides of each panel to the rat
biomarkers (data not shown).
In the case of the CKD panel, this comparison revealed
similarity in the precursor proteins of the rat and human
biomarkers: In both species the biomarkers correspond to
fragments of alpha-1-antytripsin (AAT), serum albumin (ALBU),
collagen alpha-1(I) (COL1A1), collagen alpha-2(I) (COL1A2),
collagen alpha-1(II) (COL2A1), collagen alpha-1(III) (COL3A1)
Figure 2. ZDF rats develop renal damage and cardiac structural changes after the onset of diabetes. A) Photomicrographs showing
representative sections of kidneys from LEAN and ZDF rats at 2 and 8 months of age. No changes in renal morphology are observed in LEAN rats and
in 2-month old ZDF rats. Sections from 8-month ZDF rats show glomerular sclerosis with thickening of the Bowman’s capsule and retraction of the
tuft, tubular atrophy and dilation, and hyaline casts. PAS staining/200x; B) Time course of systolic blood pressure (SBP) in LEAN control and ZDF rats.
C) Cardomyocyte area and D) Capillary density measured in cardiac tissue from LEAN and ZDF rats at 2 and 8 months of age. Values are mean6SD;
*P,0.05; **P,0.01 vs. ZDF at 2 months; uP,0.05 vs. ZDF at 4 months.
doi:10.1371/journal.pone.0051334.g002
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and alpha-2-HS-glycoprotein (AHSG). We observed analogous
regulation for fragments of AAT and ALBU (both increased in
cases compared to controls) suggesting abnormal kidney filtration.
Plasma levels and activity of AAT are reported to be
significantly decreased in diabetic patients [17]. Finding of
increased levels of urinary AAT fragments [18] suggests increased
clearance of AAT derived peptides in T2D paralleling albumin-
uria. Consistently, Varghese et al. identified urinary AAT as a
candidate biomarker for glomerular disease [19] and Talmud and
colleagues showed that AAT is associated with progression in T2D
and that low levels of AAT promote atherogenesis [20].
Pathological changes associated with T2DN also include
abnormal cross-linking of extracellular matrix compounds like
collagen due to excessive presence of advanced glycemic end
products (AGEs), resulting in abnormal matrix-matrix and matrix-
cell interaction. These disturbances in collagen breakdown and
chemical modifications of collagen contribute to atherosclerosis
and fibrosis [21,22].The modified secretion of many urinary
collagen fragments may be reflective of these morphological
observations. Thus, it is not surprising that in both species the
largest number of peptides observed as specific for disease were
COL1A1 fragments. However, the direction of the observed
regulation for rodent and human CKD markers was not the same.
In humans with CKD most COL1A1 fragments were decreased
(14 out of 15) whereas nearly 60% were increased in urine of ZDF
rats (37 out of 63), suggesting that, although displaying CKD
features (Table 1), the ZDF rat might not ‘‘model’’ the molecular
cascade promoting the changes towards renal failure in patients
with CKD.
We next investigated whether we could find ortholog peptides
between rat and the human CKD markers, assessing three levels of
similarity (Figure 1): first, we queried the data for identical
fragments (both cleavage sites identical in rat and human);
secondly, we examined for fragments with one identical cleavage
site. As the most relaxed requirement, we examined the data for
peptides from the same protein area with overlap in a minimum of
two amino acids (in all three criteria peptides were identified as
ortholog when they showed the same regulation, increase or
decrease in abundance, in both species). Surprisingly, we could not
find convincing overlap of peptides found significantly altered in
the ZDF model at 8 months with human urinary biomarkers for
CKD. We could not detect any peptide that matched the first,
most stringent criteria for comparison between the rat markers
and the 50 human CKD markers. Two peptides were identified
that had one identical cleavage site in rat and man, and further 12
could be identified that were from the same protein region and
partly overlapping (Figure 4a).
Interestingly, many of the detected fragments in the rat model
are also associated with progressive atherosclerosis. For example,
AHSG, also known as fetuin-A [23], forms soluble complexes of
otherwise insoluble calcium phosphate and thus acts as a potent
inhibitor of pathological calcification. In addition, Fetuin-A or its
variants seem to be involved in the progression of coronary
atherosclerosis [24].
Next, to obtain information on the similarity of the rat ZDF
model and human CVD, we also compared the identified markers
in rat at late stage of disease with a set of previously reported
human biomarkers for CVD [7] (Table S3). Similar precursor
proteins of the biomarkers were present in rat and human samples,
e.g.: AAT, COL1A1, COL1A2, COL2A1, and COL3A1. As in
CKD, similar expression changes for fragments of AAT (increased
in cases compared to controls in both species) were observed
pointing towards a modification of the renal filtration barrier. In
contrast however to CKD, most fragments of COL1A1 showed
the same regulation in both species: In humans with CVD 18 out
of 26 and in rats 37 out of 63 COL1A1 fragments were increased.
Ortholog peptides of the CVD markers were identified as
described above. Three rat markers were also found in the set of
50 highest significant human CVD markers
((SpGSpGPDGKTGPpGP,SpGSPGPDGKTGPpGP and AD-
GQpGAKGEPGDTGVKGDAGPpGP; the former in two vari-
ants modified by:proline and hydroxyproline, respectively). In
addition, 13 fragments had one identical cleavage site and an
additional 5 peptides were identified that showed an overlap in
minimum of two AA (Figure 4a).
Collectively, the overlap between the human CVD biomarkers
and defined biomarkers in the ZDF rats at late stage of disease was
substantial, since several similar peptides could be identified that
served as biomarkers in both cases, and with same trends of
differential expression in cases versus controls. This is in line with
data from Toblli et al. [25], indicating that ZDF rats may be an
attractive experimental model to investigate cardiovascular dam-
age related to human ‘‘metabolic syndrome’’. Furthermore,
Oltman et al. showed that vascular dysfunction in ZDF rats
progress in coronary and mesenteric arteries and precedes changes
in arteries [26]. We hypothesize that the changes observed are
associated with, but generally not a result of changes in the
glomerular filtration rate. The changes observed are most likely
due to general change of abundance in both systemic changes (e.g.
some of the collagen fragments observed) or due to functional
changes in the kidney; it is reasonable to assume that to some
extend increases in certain peptides may in part be a result of
decreased tubular reabsorption [27,28]. Tubular damage has a
significant influence on the urinary proteome also in rats, and
several of the biomarkers observed in this study were also found
Figure 3. Group specific contour plots of LEAN control rats at 2
months (n=10) and 8 months (n=7) of age and type 2 diabetes
ZDF rats at 2 and 8 months of age (n=10 at each time). Each
consisting of digitally compiled data sets of urine samples from all
individual rats in a 3D depiction. Molecular mass of the analyzed
polypeptides (0.8–25 kDa) in logarithmic scale is plotted against the CE
migration time (18–60 min) with MS signal intensity in z-axis.
doi:10.1371/journal.pone.0051334.g003
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associated with tubular damage in rats, induced with cisplatin or
gentamycin [12,29]. Also the observed sclerotic glomeruli poten-
tially contribute to urinary proteome changes.
However, we have no indication to assume that urinary
proteases are significantly involved in the generation of the
urinary peptides. This is based on the absence of significant
changes in the urinary proteome after storage at room temper-
ature for 6 h [30]. We thus hypothesize that changes in the urinary
proteome are due to changes in protease activity in the tissue [31].
In Silico Protease Identification
To obtain additional information on the underlying mechanism
for similarity or differences of urinary biomarker peptides in rat
and human, we expanded the analyses to the in silico identification
of enzymes potentially involved in the generation of the urinary
peptide fragments. The CutDB- [32] and MEROPS-database [33]
were used for protease identification based on the known cleavage
sites. We investigated the entire set of ZDF rat biomarkers and the
50 most significant human CKD and CVD biomarkers.
Since COL1A1 fregments are the predominant feature in ZDF
rat late stage biomarkers, as well as human CKD and CVD
biomarkers, we analysed in more detail the cleavage sites of all
COL1A1 peptides to predict specific proteases involved in their
generation. The N- and C-terminal cleavage sites for each
fragment (6 AA, 3 before and 3 after the observed cleavage point)
were analyzed with CutDB- and MEROPS-databases [32,33]. We
examined if either the cleavage site itself or a more relaxed pattern
(i.e. no more than 2 unmatched AA) could be found.
In total, we identified 14 different specific cleavage sites
(Table 2) for COL1A1. In Figure 4 b the number of specific
cleavage sites for matrix metallopeptidases (MMP, including MMP
2, 3, 8, 9, 12 and 13), ADAMTS5, cathepsin K (CTSK) and
thrombin (F2) and trend of differential expression for COL1A1
markers in rat and human models are given. MMP is predicted to
be increased in ZDF rats (23 cleavage sites of up- versus 6 of down
regulated fragments), decreased in human CKD (0 vs. 7) and not
clearly modified in human CVD (7 vs. 5). The increased
abundance of these peptides indicative of MMP activity suggests
an increase in MMP activity in this rat model. This observation is
matched by observation in human CVD, where such peptides are
also found increased. In contrast, peptides that likely result from
MMP activity are reduced in human DN, indicating decreased
MMP activity. The analysis of COL1A1 cleavage sites in ZDF rats
also indicated increased activity of MMP. Increased activity of
MMP13 has also been described in mouse atherosclerotic plaques
[34].
The ADAMTS5 activity appears to be highly induced in ZDF
rats (21 vs. 1) and human CVD (16 vs. 0) and possibly reduced in
human CKD (0 vs. 2), based on COL1A1 fragments in ZDF rats
and human CVD. Almost all fragments with a C-terminal PGP-
Figure 4. Similarity in amino acid sequences between rat and human biomarkers and predicted protease activities. a) Amino acid
sequence orthology between the 50 most significant human biomarkers for CKD and CVD and the defined 180 rodent markers for diabetes
associated complications. To examine the orthology between human and rat markers we applied three criteria: first, we looked for identical
fragments (both cleavage sites identical in human and rat); secondly, we looked for fragments with one identical cleavage site and third, we looked
for peptides from the same protein area with a minimum overlap in two amino acids. b) Predicted protease activities related to rat and human
COL1A1 biomarker fragments. The relative number of specific cleavage sites for MMPs, ADAMTS5, CTSK and F2 and direction of amplitude regulation
for COL1A1 markers in rat and human models are given.
doi:10.1371/journal.pone.0051334.g004
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motif are increased in rats with disease. The same regulation of
fragments with PGP-motif was previously described by Delles
et al. [7]. Furthermore, all COL1A1 cleavage sites with C-
terminal GxPGP motifs, as reported in Delles et al. [7], were also
found in ZDF rat as biomarkers for diabetes-associated compli-
cations. The increased activity of ADAMTS5 can explain the
accumulation of fragments with C-terminal PGP-motif. Another
possible explanation could be decreased activity of prolyloligo-
peptidase which cleaves specific GxPGP-motifs. Decreased activity
would result in accumulation of the PGP-containing substrate
peptides. However, such a mechanism would require a concom-
itant decrease of the expected reaction products. As this was not
observed, decreased prolyloligopeptidase activity does not appear
to be the cause for the increase in PGP-containing peptides.
The CTSK/F2 activity seems to be decreased in all pathologies.
Albeit based on a small number of observations, we find reduction
of activity in ZDF rats (4 vs. 10), as well as in human CKD (0 vs. 2)
and CVD (2 vs. 1).
As one of the most interesting findings is the presence of the
three identical peptides in the rat and CVD panels, two of which
also appear at very early stage of the disease in the former
(described below). The three ZDF rat markers identical to the
human CVD-specific COL1A1 fragments are all C-terminal
cleavage sites specific for ADAMTS5 and all N-terminus cleavage
sites are specific for MMP9 or MMP13. These fragments also
include the specific C-terminal PGP motif leading to the
hypothesis that increased activity of ADAMTS5 may be related
to molecular mechanisms of disease early development. This
hypotheses based on the cross-species molecular evaluation
presented herein may open new directions in the investigation of
early development of diabetic complications, and apparently merit
further experimental verification.
Definition of Urinary Rat Early Stage Disease Markers
We also investigated if proteomic differences could also be
observed in ZDF rats at 2 months of age where no morphological
signs of nephropathy were present. The group of LEAN controls
(n = 10) was compared to ZDF(n = 10) rat samples at the early
stage of disease (2 months of age). Five hundred forty two
significant peptides were defined and 152 of them could be
sequenced (Figure 1, Table S1). Similar to the late stage
markers, at least two fragments of aminopeptidase N, apolipopro-
tein IV, collagen, contrapsin-like protease inhibitor, prolin-rich
protein, seminal vesicle secretory protein and uromodulinwere
identified. In addition, two fragments of alpha-1-aminopeptidase
and complement C3 were identified.
Some of the identified biomarkers in ZDF rats at the early stage
of disease may not only be specific for diabetes, but could also be
biomarkers specific for early-stage diabetes associated complica-
tions. Indeed, 93 of these markers (61%) overlap with the 180
markers defined at the late stage of disease (Table S1).
Interestingly, in this set of overlapping peptides two of the three
identical markers to the human CVD markers were included
(SpGSpGPDGKTGPpGP, SpGSPGPDGKTGPpGP).
Conclusions
Molecular features are key elements in pathology and in general
the target structure for pharmacological intervention. Among
those, proteins appear especially relevant. Consequently, changes
on the proteomic level reflect the molecular pathology. Based on
these considerations, we aimed at comparing proteomic changes in
a widely used animal model to those observed in man.
The present study demonstrates the potential of (urinary)
proteome analysis for the assessment of molecular similarity of
animal models with human disease. Such assessment of similarity
appears to be one of the most important issues in the development
and application of animal models for human disease. It is expected
Table 2. Identified specific cleavage sites for COL1A1.
ZDF rat markers (8 months) human CKD markers human CVD markers
specificcleavagesites (.,) Peptidase
up-
regulated
down-
regulated
up-
regulated
down-
regulated
up-
regulated
down-
regulated
PGK.,QGA MMP: 2, 3, 8, 12, 13 23 6 0 7 7 5
PQG.,FQG MMP: 2, 3, 9, 12
PAG.,ERG MMP: 2, 9, 13
PSG.,FQG MMP: 3, 8, 9, 12, 13
PRG.,LPG MMP: 8, 9, 12, 13
PAG.,QPG MMP: 8, 9*, 12, ADAMTS4
PPG.,KNG MMP: 9, 13
QPG.,SPG MMP: 9, 13
PRG.,ERG MMP 9
PAG.,QQG MMP: 8*, 9*, 12, 13
PGP.,SGK ADAMTS5 21 1 0 2 15 0
PGP.,AGP ADAMTS5
GPR.,GPP CTSKu, F2 4 10 0 2 2 1
PPQ.,EKA CTSK
Three AA prior to and three AA after the observed cleavage point are indicated; the predicted protease (short name) and numbers on protease-to-urinary-peptide-pairs
for COL1A1 based on the rat and human dataset are also provided. The trend of regulation (up- or down- in cases versus controls per species) is also shown.
ufound only in CutDB-,
*found only in MEROPS-database.
doi:10.1371/journal.pone.0051334.t002
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that the approach presented here will open new avenues in the
establishment of appropriate animals models, and increase the
portability of results obtained in animal models towards human
disease. The data also emphasize the complex nature of diabetic
end–organ damages and the need for additional animal models
with features more analogues of those seen in human CKD. The
findings suggest a re-evaluation of the ZDF model. Based on our
results, the ZDF rat may be more suitable to study the
macrovascular branch within the pathophysiologic cascade of
diabetic angiopathies (i.e CVD), but does not appear to represent
an appropriate model for microvascular disease (i.e. CKD).
Supporting Information
Table S1 Table listing 180 identified ZDF rat peptides
specific for diabetes associated complications at late
stage of disease and the 152identified ZDF rat diabetes-
specific peptides at early stage of disease. Shown are
sequences (modified amino acids: p = hydroxyproline; k = hy-
droxylysine; m = oxidized methionine), protein names, start and
stop amino acid.In addition, statistical data for late and early stage
samples:P-values (adjusted using Benjamini-Hochberg), mean
signal intensity (amplitude) in the two groups of the cohort, and
the regulation in ZDF compared to controls. The orthology of the
late stage ZDF markers to the high significant human CKD and
CVD is also given. The 93 overlap markers between the early and
late stage of disease are marked in bold.
(XLS)
Table S2 Listed are 50 of 273 previous defined human
CKD markers [6]with lowest P-values. Shown are sequenc-
es (modified amino acids: p = hydroxyproline; k = hydroxylysine;
m = oxidized methionine), protein names, start and stop amino
acid.In addition, adjusted P-values in diabetes cohort; mean signal
intensity in DNgroup which contained 313samplesfrom diabetic
patients with CKD and in controlgroup contained 512samples-
from diabetic patients without CKD and the regulation in cases
compared to controls. The orthology to the rat markers is also
given.
(XLS)
Table S3 Listed are 50 of the 99 sequenced of 238
previous defined CVDmarkers [7] with lowest P-values-
Shown are sequences (modified amino acids: p=hy-
droxyproline; k=hydroxylysine; m=oxidized methio-
nine), protein names, start and stop amino acid. In
addition, adjusted P-values in diabetes cohort; mean signal
intensity in DN group which contained 313samplesfrom diabetic
patients with CVD and in control group contained 512samples
from diabetic patients without CVD and the regulation in cases
compared to controls. The orthology to the rat markers is also
given.
(XLS)
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